Sopharma AD (the “Company”) notifies that for May 2014 the Company recorded a decrease of sales revenues of 14% compared to the same period of 2013, including same level of domestic sales and 18% decrease of export sales. The decline in export sales is mainly due to the stagnation of the Ukrainian market and the difficult access to the eastern regions of Ukraine.

During the past five months Sopharma AD recorded a decrease of sales revenues of 2%, including 2% increase of domestic sales and 3% decrease of export sales compared to 2013.

SOPHARMA AD (the “Company”) hereby informs that from 5 June 2014 up to and including 11 June 2014 the Company bought 3 000 own shares representing 0.0023% of the share capital of the Company, to the total value of 12 930 BGN on the Bulgarian Stock Exchange, the average price per share was 4.31 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 4 941 382, representing 3.74% of the share capital of the Company.

Sopharma AD (the “Company”) hereby notifies all shareholders of the Company, that the Annual General Meeting, convened by the Board of Directors for 20 June 2014 at 11:00 will take place at Sopharma Business Towers, Building B, floor 3, 5 Lachezar Stanchev Str.. The registration begins at 9:30. All shareholders of the company are invited to participate at the General Meeting in person or by proxy.

The Board of Directors of Sopharma notifies that on its meeting carried out on June 16, 2014 it took a decision to initiate a procedure for merging Bulgarian Rose – Sevtopolis AD, VAT number 123007916 based in the city of Kazanlak on 110, “23d pehoten polk” Blvd. into Sopharma AD, under the regulation of the Commercial Code and art. 122 and the following of the Law on Public Offering of Securities and chooses “Elana Trading” AD VAT number 831470130 , based on 4, Kuzman Shapkarev Str. for a consultant in relation to the merger.

SOPHARMA AD (the “Company”) hereby informs that from 12 June 2014 up to and including 18 June 2014 the Company bought 11 400 own shares representing 0.009% of the share capital of the Company, to the total value of 48 287.40 BGN on the Bulgarian Stock Exchange, the average price per share was 4.24 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 4 951 552, representing 3.75% of the share capital of the Company.

Sopharma AD (the “Company”) notifies that on the regular General Meeting of Shareholders of Sopharma AD, conducted on 20 June 2014 in Sofia, 5 Lachezar Stanchev Str., were taken the following decisions:

Sopharma AD (the “Company”) notifies that on 19 June 2014 Sopharma AD, Sofia, UIC 831902088, hereinafter referred to as "receiving company" and Bulgarian Rose – Sevtopolis AD, Kazanluk, UIC 123007916, hereinafter referred to as "transferring company" signed a Contract for transformation through merger in accordance with the requirements of art. 262d and following of the Commercial Act (CA), as a result of which all assets of Bulgarian Rose – Sevtopolis AD shall be transferred to Sopharma AD and the latter shall become its legal successor.

SOPHARMA AD (the “Company”) hereby informs that from 26 June 2014 up to and including 2 July 2014 the Company bought 27 776 own shares representing 0.021% of the share capital of the Company, to the total value of 115 083.07 BGN on the Bulgarian Stock Exchange, the average price per share was 4.14 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 4 999 048, representing 3.79% of the share capital of the Company.

The Board of Directors of Sopharma AD (the “Company”) hereby notifies that on 2 July 2014 Sopharma AD submitted for approval the signed merger agreement between Bulgarian Rose – Sevtopolis AD and Sopharma AD and all accompanying documents to the Financial Supervision Commission.

Sopharma AD (the “Company”) notifies that for June 2014 the Company recorded a decrease of sales revenues of 8% compared to the same period of 2013, including 7% decrease of domestic sales and 9% decrease of export sales, mainly due to the situation in eastern Ukraine.

During the past six months Sopharma AD recorded a decrease of sales revenues of 6%, including 2% increase of domestic sales and 8% decrease of export sales compared to 2013.